KPNA2: A Potential Drug Target and Biomarker (G3838)

Target Name: KPNA2

NCBI ID: G3838

KPNA2

KPNA2: A Potential Drug Target and Biomarker

Kyoto Encyclopedia of Genes and Genomes (KEGG)

KPNA2, also known as KPNA2 variant 2, is a gene that encodes for a protein known as KPNA2. KPNA2 is a nuclear protein that is expressed in various tissues and cells of the body. It is a key regulator of the DNA replication process, and Its abnormal expression has been linked to various neurological and psychiatric disorders.

KPNA2 is a member of the K-type voltage-dependent Na+ channels, which are a family of transmembrane proteins that play a crucial role in the regulation of ion traffic and membrane potential. These channels are involved in many different physiological processes in the body, including the transmission of signals from the brain to the rest of the nervous system, as well as the regulation of ion channels in the heart and muscle.

KPNA2 is also known for its role in the regulation of cell growth and differentiation. It has been shown to play a role in the regulation of cell proliferation and the establishment of cell-cell adhesion. In addition, KPNA2 is involved in the regulation of cell survival and has been shown to play a role in the regulation of apoptosis.

KPNA2 has also been linked to a number of neurological and psychiatric disorders. Studies have shown that individuals with certain genetic variants, including the KPNA2 variant, are at increased risk for developing conditions such as Alzheimer's disease, Parkinson's disease, and schizophrenia. In addition, KPNA2 has also been shown to be involved in the development of certain psychiatric disorders, such as depression and anxiety.

The potential drug target for KPNA2 is based on its role in the regulation of DNA replication and its involvement in the regulation of cell growth and differentiation. Drugs that target KPNA2 have the potential to treat a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

In addition to its potential drug target, KPNA2 is also a potential biomarker for a number of neurological and psychiatric disorders. The abnormal expression of KPNA2 has been shown to be involved in the development of certain psychiatric disorders, and drugs that target KPNA2 have the potential to treat these disorders.

Overall, KPNA2 is a gene that has significant potential as a drug target and biomarker for a number of neurological and psychiatric disorders. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Karyopherin Subunit Alpha 2

Functions: Functions in nuclear protein import as an adapter protein for nuclear receptor KPNB1. Binds specifically and directly to substrates containing either a simple or bipartite NLS motif. Docking of the importin/substrate complex to the nuclear pore complex (NPC) is mediated by KPNB1 through binding to nucleoporin FxFG repeats and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to importin-beta and the three components separate and importin-alpha and -beta are re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran from importin. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus

The "KPNA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KPNA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets